# Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2

Page: https://stenobird.com/podcast/hcplive-podcasts-19526/joint-ventures-glp-1-receptor-agonists-from-metabolic-drug-to-immunomodulator-part-2
Text version: https://stenobird.com/podcast/hcplive-podcasts-19526/joint-ventures-glp-1-receptor-agonists-from-metabolic-drug-to-immunomodulator-part-2.md
Podcast: [HCPLive Podcasts](https://stenobird.com/podcast/hcplive-podcasts-19526)
Published: 2026-05-28T19:03:00+00:00
Episode link: https://audioboom.com/posts/8909063
Audio file: https://audioboom.com/posts/8909063.mp3?modified=1779994838&sid=5004077&source=rss
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/hcplive-podcasts-19526/episodes/joint-ventures-glp-1-receptor-agonists-from-metabolic-drug-to-immunomodulator-part-2
Duration seconds: 1674

## Resource

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, turn from osteoarthritis to the inflammatory arthritides — examining what early data in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and lupus can and cannot yet tell us about the role of GLP-1 receptor agonists in disease modification. “Everyone is talking about [GLP-1 RAs] and what it can do for our patients. Much more evidence is needed to be much more better understanding about increasing effects beyond weight loss is needed. And I think that evidence will be just coming out very rapidly, year by year… but I think this is not the case where we're going to wait for strong evidence, good quality RCT data before we start to start to use them,” Buss said.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/hcplive-podcasts-19526/episodes/joint-ventures-glp-1-receptor-agonists-from-metabolic-drug-to-immunomodulator-part-2/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/hcplive-podcasts-19526/joint-ventures-glp-1-receptor-agonists-from-metabolic-drug-to-immunomodulator-part-2.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.